04:15 , Mar 23, 2019 |  BioCentury  |  Product Development

Baby steps beyond beta amyloid

Companies are taking steps -- baby steps -- to test new targets in pathways such as neuroinflammation and neuroprotection as a means to treat Alzheimer’s disease. The failure of aducanumab won’t be the final nail...
19:22 , Mar 22, 2019 |  BC Extra  |  Company News

Sanofi, Lexicon get complete response letter for Zynquista

Sanofi said FDA issued a complete response letter to an NDA for Zynquista sotagliflozin as an adjunct to insulin for adults with Type I diabetes. The news sent shares of partner Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX)...
15:00 , Mar 21, 2019 |  BC Extra  |  Company News

Celgene looks to AI company Exscientia to speed up small molecule discovery

Two months after backing Exscientia in a series B round, Celgene signed a three-year deal with the AI company to discover small molecules for three of Celgene's oncology and autoimmunity programs. Exscientia Ltd. (Oxford, U.K.)...
17:37 , Mar 18, 2019 |  BC Extra  |  Clinical News

Dermira jumps on Phase IIb atopic dermatitis readout

Dermira added $5.77 (84%) to $12.61 on Monday after reporting that all three doses of lebrikizumab met the primary endpoint in a Phase IIb trial to treat adults with moderate-to-severe atopic dermatitis. Dermira Inc. (NASDAQ:DERM)...
17:35 , Mar 15, 2019 |  BC Week In Review  |  Company News

Principia reacquires immunoproteasome inhibitors from AbbVie

Principia and AbbVie agreed to end a 2017 deal to develop oral immunoproteasome inhibitors to treat autoimmune disorders. Principia Biopharma Inc. (NASDAQ:PRNB), which regained rights to the program, said AbbVie Inc. (NYSE:ABBV) had determined that...
00:00 , Mar 15, 2019 |  BC Week In Review  |  Financial News

Sanofi raises €2B via bond issue

Sanofi raised €2 billion ($2.2 billion) through the sale of fixed rate notes. Underwriters were BofA Merrill Lynch, Natixis, ING and Santander. The bonds were broken into three tranches. The first set is due March...
20:07 , Mar 13, 2019 |  BC Extra  |  Financial News

BioNTech mum on $800M IPO report

Amid a report that it will seek an $800 million IPO, BioNTech told BioCentury it is still evaluating all financial options. Citing undisclosed people familiar with the IPO, Reuters has reported that BioNTech AG (Mainz,...
13:06 , Mar 13, 2019 |  BC Innovations  |  Distillery Therapeutics

IKKβ inhibition for tendinopathy

DISEASE CATEGORY: Musculoskeletal INDICATION: Musculoskeletal Patient sample, cell culture and mouse studies suggest inhibiting IKKβ could help treat tendinopathy. In tendon tissues samples from patients with rotator cuff disease, levels of IKKβ protein were higher...
22:32 , Mar 11, 2019 |  BC Extra  |  Company News

FDA approves Dupixent for atopic dermatitis in adolescents

FDA on Monday approved the first biologic for adolescents with moderate-to-severe atopic dermatitis, Dupixent dupilumab from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and partner Sanofi (Euronext:SAN; NYSE:SNY). The partners already market the human mAb targeting the α...
22:15 , Mar 8, 2019 |  BC Extra  |  Company News

FDA panel does not back broad reach of Sanofi's dengue vaccine

Sanofi's dengue vaccine did not win the support of an FDA panel for its proposed population of individuals ages 9-45 Thursday, but the panel did back the vaccine's use in adolescents. The vote came as...